Bladder Cancer Treatment Options in Turkey: How TURBT, BCG Immunotherapy and Robotic Cystectomy Are Chosen

Bladder Cancer Treatment Options in Turkey

Every treatment decision follows from one question: has the tumour reached the muscle wall? About 75 percent of bladder cancers have not, and the bladder is kept and treated from the inside. The remaining 25 percent have, and need systemic treatment and usually removal of the bladder.

What Is Bladder Cancer?

Bladder cancer is the uncontrolled growth of the urothelial cells lining the inside of the bladder. Roughly 90 percent of cases are urothelial carcinoma, 5 percent squamous cell carcinoma and 2 percent adenocarcinoma. Grade matters more than size: low grade tumours recur but rarely invade, while high grade tumours are treated intensively even when still superficial.

Symptoms and Risk Factors

Painless blood in the urine is the first sign in about 80 percent of cases. It comes and goes, and the fact that it stops does not mean the cause has gone. Passing urine more often, urgency, burning and pelvic pain follow. Flank pain, weight loss and bone pain suggest advanced disease.

Smoking is the leading cause, behind an estimated 50 to 65 percent of cases in men and 20 to 30 percent in women. Occupational exposure to aromatic amines in the paint, rubber, tyre, leather and printing industries follows. Median age at diagnosis is 73, and men are affected three to four times as often as women.

Diagnosis Before Treatment

Diagnosis starts with urine cytology and ultrasound, then CT urography to image the kidneys, ureters and bladder together. MRI judges how deeply a tumour has invaded, which is what drives staging.

Cystoscopy remains the gold standard, because it shows the bladder lining directly. A thin camera is passed along the urethra under local anaesthetic. Blue light cystoscopy adds a fluorescent agent that makes tumour tissue glow, and it is clearly superior for finding carcinoma in situ, which is flat and easily missed under white light. Narrow band imaging enhances the vessel pattern so small lesions stand out.

TURBT, Transurethral Resection

TURBT is both the diagnosis and the first treatment. Under general or spinal anaesthetic a resectoscope is passed along the urethra and the tumour is removed with electrical current, with no external incision. A single dose of intravesical mitomycin follows the first resection.

The pathology report answers the questions that decide everything afterwards: has the muscle been reached, were the margins clear, and what is the grade. In high risk cases a second look TURBT is performed after four to six weeks, because residual tumour is found in a significant proportion of patients at that point.

Intravesical BCG and Chemotherapy

BCG, Bacillus Calmette Guerin, is a weakened tuberculosis vaccine instilled into the bladder. It provokes a local immune response against remaining cancer cells, which is why it is immunotherapy rather than chemotherapy. Induction is one instillation weekly for six weeks, followed by maintenance.

Radical Cystectomy and Urinary Diversion

Once the muscle is involved, cisplatin based chemotherapy is given first, which improves five year survival by roughly 5 to 10 percent over surgery alone. Radical cystectomy then removes the bladder with the prostate in men or the uterus in women, along with the pelvic lymph nodes. Robotic cystectomy means less blood loss, faster return of bowel function and less pain, with cancer control comparable to open surgery.

Chemotherapy, Immunotherapy and Radiotherapy

Systemic chemotherapy is cisplatin based: gemcitabine with cisplatin is now more commonly used than MVAC because it is better tolerated, and carboplatin substitutes where kidney function rules cisplatin out. Checkpoint immunotherapy follows when chemotherapy stops working: pembrolizumab and nivolumab target PD 1, while atezolizumab, durvalumab and avelumab target PD L1.

Targeted options include erdafitinib for tumours carrying an FGFR mutation and enfortumab vedotin, an antibody drug conjugate directed at Nectin 4. Trimodal therapy, combining complete resection with chemotherapy and radiotherapy, preserves the bladder in roughly 50 to 70 percent of carefully selected patients, with cystectomy held in reserve.

Why Patients Travel to Turkey for Treatment

According to the Turkish Statistical Institute, about 1.5 million people travelled to Turkey for medical treatment in 2023. Turkey also has one of the largest groups of hospitals outside the United States accredited by Joint Commission International. The reasons for coming, however, are not the same everywhere, and it is worth being specific.

Patients from the United States and Canada

For American patients the answer is almost always cost. Bladder cancer carries the highest lifetime treatment cost per patient of any cancer, estimated at 96,000 to 187,000 dollars in the United States, because surveillance cystoscopy and repeat resection continue for years rather than months. That burden falls on the patient through deductibles and coinsurance even when insured. Turkish private hospitals perform the same robotic cystectomy with the same da Vinci systems for a fraction of it. For Canadian patients the driver is different: care is publicly funded, so the issue is time. The Fraser Institute's annual survey has put the median wait from family doctor referral to treatment at around 27 weeks, and bladder cancer is a disease where months matter, since survival falls from about 97 percent while confined to the lining to 40 percent once nodes are involved.

Patients from Europe

European patients come for proximity and continuity. Istanbul is a three to four hour flight from most European capitals, which matters for a cancer requiring cystoscopy every three months rather than one operation and a farewell. Waiting lists are the second reason: NHS England's 62 day standard from urgent referral to first treatment has been missed repeatedly, and similar pressure exists across the public systems of Western Europe. The third reason is the quiet one. Turkish urology works to European Association of Urology guidelines, the same protocol your urologist at home follows, so the risk grouping, BCG schedule and surveillance plan transfer back without translation or argument.

Patients from Africa

African patients come for technology that is not available at home. The International Atomic Energy Agency's directory of radiotherapy centres records that around half of African countries have no radiotherapy facility at all, and robotic surgery and blue light cystoscopy are rarer still. Access is the second reason: Turkish Airlines serves more African destinations than any other carrier, so Istanbul is often a direct flight where Western Europe is not. There is also a clinical reason. Where Schistosoma haematobium is endemic, squamous cell carcinoma makes up a far larger share of bladder cancers than the 5 percent seen worldwide, and it tends to present muscle invasive, which means these patients need cystectomy and reconstruction rather than a course of BCG.

Follow up and Recurrence

Bladder cancer is the most surveillance intensive urological cancer, and most recurrences are found in patients who feel completely well. After treatment for superficial disease, cystoscopy and cytology run every 3 months for 2 years, every 6 months to year 5, then annually, with yearly imaging of the kidneys and ureters. After cystectomy, CT and blood tests run every 3 to 4 months for 2 years, then every 6 months. Follow up can be shared with your own urologist at home.

Survival Outcomes

The figures below come from the SEER programme of the United States National Cancer Institute and describe five year relative survival. They are population averages, not a prediction for any individual.

Frequently Asked Questions